- Email: [email protected]
Current Status and Future Perspective of Therapeutic Strategy for Metastatic Colorectal Cancer in Japan
Annals of Oncology 25 (Supplement 5): v23, 2014 doi:10.1093/annonc/mdu414.2
International Session 7: ‘Future perspective of therapeutic strategy for metastatic colorectal cancer’ 3
CURRENT STATUS AND FUTURE PERSPECTIVE OF THERAPEUTIC STRATEGY FOR METASTATIC COLORECTAL CANCER IN JAPAN
Kentaro Yamazaki Division of Gastrointestinal Oncology, Shizuoka Cancer Center
abstracts
In the last decade, unprecedented advances have been seen in the treatment of metastatic colorectal cancer (mCRC). Clinical developments of new active agents such as irinotecan, oxaliplatin, bevacizumab, cetuximab and panitumumab have contributed to this great progress in the prognosis of mCRC. Recently, a multikinase inhibitor called regorafenib
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v23/2240162 by guest on 25 October 2019
IS7
showed survival benefits for patients with mCRC who are refractory to all standard therapies. Also, a novel oral nucleoside antitumor agent known as TAS-102 showed promising efficacy in the same population. Therefore, there is current positive development of various new drugs. On the other hand, the development of many active agents and combination chemotherapies has caused the treatment strategy for mCRC to be complicated. So it is necessary to settle clinical questions in order to optimize this complex treatment strategy. With regard to first line chemotherapy, two major clinical questions remain. The first question is whether bevacizumab or anti-EGFR antibodies are more effective for patients with previously untreated KRAS wild-type mCRC. Last year, the PEAK and FIRE-3 studies showed promising survival benefits for anti-EGFR antibody-containing chemotherapy compared with bevacizumab-containing chemotherapy, and the result of the CALGB80405 trial will be presented at the ASCO annual meeting this year. The second question is whether oxaliplatin or irinotecan-based chemotherapy is more suitable for molecular targeting agents. The West Japan Oncology Group conducted a randomized, open-label, phase III trial (4407G study) to assess the non-inferiority of FOLFIRI + bevacizumab to mFOLFOX6 + bevacizumab in progression-free survival. In this session, I would like to introduce the result of the WJOG4407G study and discuss the future perspective of treatment strategy for mCRC.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
International Session 7: ‘Future perspective of therapeutic strategy for metastatic colorectal cancer’ 3
CURRENT STATUS AND FUTURE PERSPECTIVE OF THERAPEUTIC STRATEGY FOR METASTATIC COLORECTAL CANCER IN JAPAN
Kentaro Yamazaki Division of Gastrointestinal Oncology, Shizuoka Cancer Center
abstracts
In the last decade, unprecedented advances have been seen in the treatment of metastatic colorectal cancer (mCRC). Clinical developments of new active agents such as irinotecan, oxaliplatin, bevacizumab, cetuximab and panitumumab have contributed to this great progress in the prognosis of mCRC. Recently, a multikinase inhibitor called regorafenib
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v23/2240162 by guest on 25 October 2019
IS7
showed survival benefits for patients with mCRC who are refractory to all standard therapies. Also, a novel oral nucleoside antitumor agent known as TAS-102 showed promising efficacy in the same population. Therefore, there is current positive development of various new drugs. On the other hand, the development of many active agents and combination chemotherapies has caused the treatment strategy for mCRC to be complicated. So it is necessary to settle clinical questions in order to optimize this complex treatment strategy. With regard to first line chemotherapy, two major clinical questions remain. The first question is whether bevacizumab or anti-EGFR antibodies are more effective for patients with previously untreated KRAS wild-type mCRC. Last year, the PEAK and FIRE-3 studies showed promising survival benefits for anti-EGFR antibody-containing chemotherapy compared with bevacizumab-containing chemotherapy, and the result of the CALGB80405 trial will be presented at the ASCO annual meeting this year. The second question is whether oxaliplatin or irinotecan-based chemotherapy is more suitable for molecular targeting agents. The West Japan Oncology Group conducted a randomized, open-label, phase III trial (4407G study) to assess the non-inferiority of FOLFIRI + bevacizumab to mFOLFOX6 + bevacizumab in progression-free survival. In this session, I would like to introduce the result of the WJOG4407G study and discuss the future perspective of treatment strategy for mCRC.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].